Clinical Trial Detail

NCT ID NCT01203722
Title Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

hematologic cancer

Therapies

Tacrolimus

Sirolimus

Cyclophosphamide + Fludarabine + Mycophenolate mofetil

Age Groups: adult child

No variant requirements are available.